Gzmk Antibody

What is Granzyme K and why is it important in immunological research?

Granzyme K (GZMK) belongs to the family of serine proteases stored in granules inside cytotoxic cells of the immune system. It plays significant roles in inflammation and tumorigenesis. Unlike Granzyme B, GZMK does not primarily induce apoptotic cell death but instead activates other inflammatory pathways. There are five human granzymes (GrA, GrB, GrH, GrK, and GrM) currently identified, while mice have ten known granzymes (GrA-G, GrK, GrM, and GrN) .

GZMK is expressed by:

• Cytotoxic T lymphocytes

• Natural killer T cells (NKT)

• γδ T cells

• CD56bright+ NK cells

• CD8+ T cells (38.4 ± 13.9% in peripheral blood)

• A subset of CD4+ T cells (mainly effector memory cells)

• Mucosal-associated invariant T (MAIT) cells

The scientific importance of GZMK has expanded as research has shown its role in various disease contexts, including its potential as a prognostic marker in cancer and its involvement in inflammatory diseases such as rheumatoid arthritis .

What types of GZMK antibodies are available for research applications?

Several types of GZMK antibodies are available for research, varying in host species, clonality, and targeting domains:

When selecting an antibody, consider:

• The specific application (detection method)

• Required cross-reactivity (human, mouse, rat)

• The particular epitope/domain of interest

• Validation data available for your specific application

How do I determine the appropriate GZMK antibody dilution for my experiment?

Determining the optimal dilution for GZMK antibodies is critical for experimental success. While manufacturers provide recommended dilutions, these should be considered starting points for optimization in your specific system:

It is strongly recommended to perform a titration experiment with a positive control sample to determine the optimal antibody concentration for your specific application and sample type .

What are the recommended protocols for GZMK immunohistochemistry staining?

For successful IHC detection of GZMK in tissue samples, follow these methodological guidelines:

Protocol overview for GZMK IHC:

• Section preparation: Use 4-6 μm sections from formalin-fixed, paraffin-embedded tissues

• Deparaffinization: Standard xylene and ethanol series

• Antigen retrieval: Critical step - use either:

  • TE buffer pH 9.0 (primary recommendation)

  • Citrate buffer pH 6.0 (alternative method)

• Peroxidase blocking: 3% H₂O₂ for 10 minutes

• Protein blocking: 5% normal serum for 1 hour

• Primary antibody incubation: Anti-GZMK (dilution 1:500-1:2000) overnight at 4°C

• Secondary antibody: Species-appropriate HRP-conjugated antibody

• Detection: DAB substrate solution

• Counterstaining: Hematoxylin

• Dehydration and mounting

Positive controls should include human tonsillitis tissue, which consistently shows GZMK expression. For scoring GZMK expression, use a combined approach assessing both staining intensity (0-3+) and percentage of positive cells (0-4 scale) .

How can I optimize Western blot detection of GZMK protein?

Western blot detection of GZMK requires careful optimization due to its relatively low molecular weight and potential cross-reactivity with other granzymes:

Optimized Western blot protocol for GZMK:

• Sample preparation: Include protease inhibitors to prevent degradation

• Gel selection: 12-15% SDS-PAGE gels are optimal for the ~29 kDa GZMK protein

• Transfer conditions: Semi-dry or wet transfer (100V for 60-90 minutes)

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour

• Primary antibody: Anti-GZMK (1:500-1:2000 dilution) overnight at 4°C

• Washing: 3-5 times with TBST

• Secondary antibody: HRP-conjugated anti-host species (1:5000-1:10000)

• Detection: ECL substrate with appropriate exposure time

Important considerations:

• Expected molecular weight is approximately 29 kDa, but observed bands may appear at ~39 kDa

• GZMK is primarily expressed in immune cells, so appropriate positive controls are essential (peripheral blood mononuclear cells, NK-92 cells)

• Use fresh samples and avoid repeated freeze-thaw cycles

What flow cytometry strategies are most effective for GZMK detection in different lymphocyte populations?

Flow cytometry is particularly valuable for analyzing GZMK expression in distinct immune cell populations:

Effective flow cytometry approach:

• Sample preparation: Fresh PBMCs or tissue-derived lymphocytes

• Surface staining: First stain for lineage markers (CD3, CD4, CD8, CD56, etc.)

• Fixation/permeabilization: Critical for intracellular GZMK detection

  • Use commercial kits designed for intracellular proteins

• GZMK antibody staining: 1.2 μg/10⁶ cells, typically with clone GM-26E7 or GM-24C3

• Multi-parameter analysis: Include markers for:

  • T cell subsets (naïve/memory/effector)

  • Activation status

  • Other granzymes (particularly GZMB for co-expression analysis)

For comprehensive immune profiling, consider this panel design:

This approach allows for detailed characterization of GZMK+ cells across multiple immune populations .

How can I validate the specificity of my GZMK antibody?

Antibody validation is crucial to ensure specific detection of GZMK without cross-reactivity with other granzymes:

Comprehensive validation approach:

• Positive and negative controls:

  • Positive: Human tonsillitis tissue, activated PBMCs, NK-92 cells

  • Negative: Tissues known to lack GZMK expression

• Specificity testing:

  • Western blot with recombinant GZMK alongside other granzymes

  • Blocking peptide experiments to confirm epitope specificity

  • siRNA knockdown of GZMK in expressing cell lines

• Cross-reactivity assessment:

  • Test against recombinant GZMA, GZMB, and GZMM

  • Particularly important since some monoclonal antibodies (clones GM-24C3 and GM-26E7) have been specifically verified not to cross-react with human granzymes A, B, or M

• Multi-method concordance:

  • Compare results across different detection methods (IHC, WB, IF, flow)

  • Different antibodies targeting distinct epitopes should show similar patterns

A robust validation strategy ensures reliable and reproducible results in downstream applications .

What are common problems with GZMK detection and how can they be resolved?

Researchers frequently encounter several challenges when working with GZMK antibodies:

For persistent issues, consider these advanced troubleshooting approaches:

• For IHC/IF: Try alternative fixation methods or different antigen retrieval buffers

• For WB: Test different lysis buffers and blocking reagents

• For flow cytometry: Optimize fixation/permeabilization conditions for intracellular staining

How can GZMK antibodies be used to investigate its role in cancer immunotherapy responses?

Recent research has highlighted GZMK's potential role in predicting and influencing immunotherapy responses in cancer:

Methodological approaches:

• Multiplex immunohistochemistry:

  • Co-staining GZMK with other immune markers (CD8, PD-1, CTLA-4)

  • Spatial analysis of GZMK+ cells relative to tumor cells

• Correlation with clinical outcomes:

  • Pre-treatment tumor biopsies analyzed for GZMK expression

  • Longitudinal sampling during treatment course

• Flow cytometric analysis of circulating immune cells:

  • Monitor GZMK+ cell populations before and during therapy

  • Assess activation status and functionality

Research findings have shown that GZMK expression correlates significantly with immune checkpoint molecules, including:

• CTLA4 (Cor = 0.856, P < 0.001)

• PD-1 (Cor = 0.82, P < 0.001)

• PD-L1 (Cor = 0.56, P < 0.001)

• CD48 (Cor = 0.75, P < 0.001)

• CCR7 (Cor = 0.856, P < 0.001)

Importantly, studies have indicated that high GZMK expression enhances patient responsiveness to immunotherapy, with higher levels observed in responsive patients compared to non-responsive ones .

What strategies can be used to analyze GZMK's functional role separate from other granzymes?

Distinguishing GZMK's specific functions from other granzymes requires sophisticated experimental approaches:

Strategic methodologies:

• Selective inhibition:

  • Use specific inhibitors or neutralizing antibodies against GZMK

  • Compare effects with inhibitors of other granzymes (especially GZMB)

• Recombinant protein studies:

  • Purified active GZMK can be used in target cell assays

  • Analyze non-apoptotic outcomes vs. classic GZMB-mediated cell death

• Gene editing approaches:

  • CRISPR/Cas9 knockout of GZMK in relevant cell lines

  • Single-cell cloning to establish pure populations

• Substrate identification:

  • Proteomic approaches to identify GZMK-specific substrates

  • Validation with in vitro cleavage assays using recombinant proteins

Research has demonstrated that unlike GZMB, GZMK does not induce classic apoptotic cell death. Instead, it activates alternative pathways:

• Induces production of IL-6 and CCL2 from fibroblasts

• Generates reactive oxygen species (ROS) when delivered intracellularly

• Synergizes with IFN-γ to enhance inflammatory cytokine production

• Cleaves complement components like C4 to drive complement activation

How can GZMK expression patterns be integrated with single-cell RNA sequencing data for comprehensive immune profiling?

Integrating GZMK protein expression data with single-cell RNA sequencing represents a powerful approach for comprehensive immune profiling:

Integrated analysis workflow:

• Multi-omics experimental design:

  • Process parallel samples for protein detection and scRNA-seq

  • Consider CITE-seq approaches for simultaneous measurement

• Cell population identification:

  • Use scRNA-seq for unbiased cell clustering

  • Map GZMK expression across identified populations

• Correlation analysis:

  • Correlate GZMK protein levels with transcript abundance

  • Identify co-expressed genes and relevant pathways

• Trajectory analysis:

  • Place GZMK+ cells in differentiation trajectories

  • Identify precursor and effector states

Published research has found GZMK expression in:

• 20-60% of CD8+ T cells and up to 30% of CD4+ T cells in tissues

• Variable expression depending on disease state

• Distinct patterns compared to GZMB (detected in 10-50% of CD8+ T cells)

Transcriptional analysis reveals that GZMK+GZMB+ CD8+ T cells represent a distinct state with:

• Downregulation of S1PR1 and SELL (CD62L)

• Downregulation of memory precursor genes (IL7R, TCF7)

• Upregulation of effector markers but in patterns distinct from GZMB-only cells

What is currently known about GZMK's role in the complement activation pathway?

Recent research has uncovered GZMK's unexpected role in complement activation pathways:

Key mechanistic findings:

• GZMK directly cleaves complement components:

  • Cleaves C4 into C4b, similar to the action of C1s

  • May potentially cleave C2 into C2a

  • These actions can lead to formation of C3 convertase (C4bC2a)

• GZMK-driven complement activation differs from other pathways:

  • Does not require the classic C1 complex activation

  • Acts independently of other granzymes (GZMA cannot substitute)

• Constitutive release patterns:

  • CD8+ T cells constitutively synthesize and release GZMK without TCR stimulation

  • This allows continuous access to extracellular substrates

  • Creates potential for ongoing complement activation in tissues with GZMK+ cells

These findings suggest GZMK drives a previously unrecognized pathway of complement activation, with important implications for inflammatory diseases and tissue injury .

How does GZMK contribute to tissue inflammation in autoimmune diseases?

GZMK plays multiple roles in promoting tissue inflammation in autoimmune contexts:

Inflammatory mechanisms:

• Fibroblast activation:

  • GZMK activates synovial fibroblasts to produce pro-inflammatory cytokines

  • Induces IL-6 and CCL2 production in a dose-dependent manner

  • Effect occurs without requiring perforin or internalization

• Synergy with other inflammatory mediators:

  • Augments the effect of IFN-γ on cytokine production

  • Creates feed-forward inflammatory loops

• Reactive oxygen species (ROS) generation:

  • When delivered intracellularly, GZMK induces dose-dependent ROS production

  • Contributes to oxidative stress in inflamed tissues

• Non-cytotoxic immune regulation:

  • Does not induce cell death (no LDH release detected)

  • Instead modulates inflammatory pathways without eliminating cells

In rheumatoid arthritis, GZMK+ T cells form a core population in inflamed synovium, contributing to pathology through these non-cytotoxic mechanisms rather than through classic cytotoxic activity .

What emerging technologies are advancing our understanding of GZMK biology?

Several cutting-edge technologies are transforming our understanding of GZMK biology:

Emerging technological approaches:

• Spatial transcriptomics and proteomics:

  • Mapping GZMK expression with spatial context

  • Identifying microanatomical niches of GZMK+ cells

• Live-cell imaging of GZMK release:

  • Fluorescently tagged GZMK constructs

  • Real-time visualization of granzyme release and target engagement

• Targeted proteomics:

  • Identifying GZMK-specific substrates in different cell types

  • Mapping cleavage sites and consequences

• Advanced genetic models:

  • Cell-type specific and inducible GZMK deletion

  • Humanized mouse models expressing human GZMK

• Systems immunology approaches:

  • Integration of GZMK data with other -omics datasets

  • Network analysis to position GZMK in immune response networks

These technologies are particularly valuable for understanding GZMK's unique roles distinct from other granzymes, including its cell-activating rather than cell-killing functions and its involvement in complement activation pathways .